Apellis Pharmaceuticals Inc (APLS) is a biopharmaceutical company that focuses on developing novel therapies for complement-mediated diseases. The company's lead product candidate, pegcetacoplan, is a targeted C3 therapy that is designed to regulate excessive complement activation, which is implicated in several diseases, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and age-related macular degeneration (AMD).
Apellis is also developing other product candidates that target different components of the complement system, including APL-9, which is designed to inhibit C3, and APL-2, which is designed to inhibit C5. The company has several clinical programs underway, including Phase III trials of pegcetacoplan for PNH and aHUS, and Phase II trials of pegcetacoplan for AMD and other complement-mediated diseases.
Apellis is headquartered in Waltham, Massachusetts, and was founded in 2009. The company went public in 2017 and is listed on the NASDAQ stock exchange under the ticker symbol APLS.
Apellis Pharmaceuticals Inc (APLS) is a biopharmaceutical company that focuses on developing novel therapies for complement-mediated diseases. The company's lead product candidate, pegcetacoplan, is a targeted C3 therapy that is designed to regulate excessive complement activation, which is implicated in several diseases, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and age-related macular degeneration (AMD).